Crizotinib is an oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK) approved by US Food and Drug Administration (FDA) for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK rearrangements [10]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.